Lung Cancer and Immunity Markers.
Lung Cancer and Immunity Markers.
复制标题
DOI：
10.1158/1055-9965.epi-20-0716
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Dubinett SM
中科院分区：
文献类型：
--
作者：
Lim RJ;Liu B;Krysan K;Dubinett SM
对肺癌生物学和肿瘤进展机制的深入了解促进了肺癌治疗的重大进展。仍然迫切需要开发创新的方法，以便在肺癌发展的最早阶段发现和拦截肺癌。基因组学、计算生物学和创新技术的最新进展为识别与早期肺癌发生相关的肿瘤微环境中的免疫格局提供了独特的机会，并为进一步深入了解肺癌的进化机制提供了进一步的见解。本综述将着重介绍免疫编辑的概念，并重点介绍近期评估肺部癌前病变和早期非小细胞肺癌免疫变化和生物标志物的研究。以检查点抑制和抑制性免疫细胞增加为特征的亲肿瘤免疫反应和抗肿瘤免疫反应同时降低与肿瘤进展相关。潜在的与早期肺癌相关的全身性生物标记物将随着目前肺癌拦截的临床努力而被强调。在肺癌进展到晚期之前，专注于开发新的癌症拦截策略的研究可能会导致肺癌治疗的范式转变，并对临床结果产生重大影响。
An in-depth understanding of lung cancer biology and mechanisms of tumor progression has facilitated significant advances in the treatment of lung cancer. There remains a pressing need for the development of innovative approaches to detect and intercept lung cancer at its earliest stage of development. Recent advances in genomics, computational biology and innovative technologies offer unique opportunities to identify the immune landscape in the tumor microenvironment associated with early-stage lung carcinogenesis, and provide further insight in the mechanism of lung cancer evolution. This review will highlight the concept of immunoediting and focus on recent studies assessing immune changes and biomarkers in pulmonary premalignancy and early-stage NSCLC. A pro-tumor immune response hallmarked by an increase in checkpoint inhibition and inhibitory immune cells and a simultaneous reduction in anti-tumor immune response have been correlated with tumor progression. The potential systemic biomarkers associated with early lung cancer will be highlighted along with current clinical efforts for lung cancer interception. Research focusing on the development of novel strategies for cancer interception prior to the progression to advanced stages will potentially lead to a paradigm shift in the treatment of lung cancer and have a major impact on clinical outcomes.